CAM
NTLA icon

Creekmur Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Creekmur Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$668K Sell
38,677
-19,923
-34% -$245K 0.11% 105
2025
Q2 		$550K Buy
58,600
+17,654
+43% +$145K 0.1% 125
2025
Q1 		$291K Buy
+40,946
New +$414K 0.06% 152

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creekmur Asset Management's NTLA Position: Q3 2025 in Review

Creekmur Asset Management reduced its Intellia Therapeutics (NTLA) stake by 34% in Q3 2025, selling an estimated $245K and leaving 38,677 shares worth $668K. The position accounts for 0.11% of the portfolio, ranked #105.

Creekmur Asset Management first reported a position in NTLA in Q1 2025 and has held it in 3 quarters since. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Creekmur Asset Management held 38,677 shares of Intellia Therapeutics worth $668K as of Q3 2025.
  • Creekmur Asset Management sold 19,923 Intellia Therapeutics shares in Q3 2025, an estimated $245K.
  • Intellia Therapeutics made up 0.11% of Creekmur Asset Management's portfolio in Q3 2025, its #105 holding.
  • Creekmur Asset Management first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Creekmur Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.